Replies to post #399396 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

It is NWBO’s space to do with as it needs. It can use that space for production at any time. It currently is too much space.

It is not up to me to prove what is alleged by critics. The arrangements are clear and have been explained. The 10-Q explains there are 40 people working on production for NWBO via advent. Do you see their salaries or long-term benefits on the NWBO balance sheet? Those are costs that will be born by Advent. Now if NWBO fails, there is some time for Advent to adjust, but these are not NWBO employees and European costs and obligations for employees are different than in the US, which has very thin protection for employees. So presumably NWBO or any company that contracts for labor can’t be entirely without burden.

But why would you question that Advent has to pay to produce for other customers in a space controlled by NWBO? You think they will just receive it for free? Do you think NWBO will pay for production of cell and gene therapies at other clients when Advent ultimately gets new business? That would I am certain be actionable as a matter of law.

But critics allege nonsense without saying anything in fact, and if they said something real, it would necessarily be actionable. I see little indication of action, because they have no basis for it and if they harass the company further, on baseless allegations, you can bet that some people and some firms will likely not just be liable to NWBO, but they might even see a novel shareholder’s lawsuit for damages.